

Aventis Pharmaceuticals Inc.

Patent Department

July 11, 2002

VIA COURIER

United States Patent and Trademark Office
Crystal Mall 1
1911 South Clark Street
7th Floor Receptionist
Arlington, VA 22202

Attn: Examiner Chih-Min Kam

Re: United States Patent Application

Applicants : Christine Icard-Liepkalns *et al.*
Title : POLYPEPTIDES OF THE "BASIC-HELIX-LOOP-HELIX" bHLH
FAMILY, CORRESPONDING NUCLEIC ACID SEQUENCES
Filed : June 16, 2000
Serial No. : 09/595,947
Docket No. : ST96042A US

Dear Examiner Kam:

In response to your telephone request of July 11, 2002, I am enclosing herein the following:


1. a replacement diskette containing the sequence listing for the above-identified Application; and
2. copies of documents filed previously with the United States Patent and Trademark Office on May 16, 2002.

If you require any additional materials, please do not hesitate to contact me.

Very truly yours,

AVENTIS PHARMACEUTICALS INC.

By:


William C. Coppola

ENCLOSURE

#11 WP
Letter
Aventis
8/13/02
RECEIVED
JUL 15 2002
TECH CENTER 1600/2900

RECEIVED
JUL 17 2002
TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 15 2002 ✓


TECH CENTER 1600/2900

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/595,947	06/16/2000	Christine Icard-Liepkalns	ST96042 AUS.	2918

5487 7590 05/02/2002

AVENTIS PHARMACEUTICALS, INC.
PATENTS DEPARTMENT
ROUTE 202-206, P.O. BOX 6800
BRIDGEWATER, NJ 08807-0800



EXAMINER

KAM, CHIH MIN

ART UNIT	PAPER NUMBER
----------	--------------

1653

DATE MAILED: 05/02/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Prepare Reply To 2nd Seq. Reqmts - 5/13/02
Reply To Sequence Reqmts - 6/2/02

ACTION DUE	<u>Reply To Seq. Reqmt's/Deadline - 11/2/02</u>
DUE DATE	<u>↑</u>
DKTD BY	<u>Jes 5/9/02</u>
ATTY	<u>WCC</u>



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

9

DATE MAILED:

RECEIVED

JUL 15 2002

TECH CENTER 1600/2900

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The communication filed November 15, 2001 is not fully responsive to the Office communication mailed September 28, 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (703) 308-9437. The examiner can normally be reached on 8:00-4:30 from Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (703) 308-2923. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>>, EFS Submission User Manual - ePAVE)

2. Mailed to:

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:

U. S. Patent and Trademark Office
2011 South Clark Place

Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

RECEIVED

JUL 15 2002

TECH CENTER 1600/2900

4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202

Chih-Min Kam, Ph.D.
May 1, 2002

CHK

Christopher S. Low
CHRISTOPHER S. P. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1000

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
ICARD-LIEPKALNS ET AL.

Examiner: KAM, CHIH MIN

RECEIVED

Art Unit: 1653

JUL 15 2002

Application No.: 09/595,947

Filed: **JUNE 16, 2000**

TECH CENTER 1600/2900

Title: **POLYPEPTIDES OF THE "BASIC-
HELIX-LOOP-HELIX" bHLH
FAMILY, CORRESPONDING
NUCLEIC ACID SEQUENCES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

5/16/02
Date of Deposit

Signature *William C. Coppola*

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

William C. Coppola
William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Aventis Docket No. ST96042AUS